Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-07-22
2008-07-22
Rao, Manjunath (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S007210, C435S007800, C436S536000, C436S512000, C436S538000, C436S063000
Reexamination Certificate
active
10963855
ABSTRACT:
The invention provides a method for determining the activation status of receptor tyrosine kinase (RTK) pathways in either cell samples or patient samples by measuring receptor dimerization and relative amounts of protein-protein complexes or activated effector proteins that are characteristic of an RTK pathway. The invention also provides a method of using such status information to select patients responsive to pathway-specific drugs, and more particularly, to methods for measuring ErbB receptors and receptor complexes and using such information to select patients responsive to ErbB pathway-specific drugs. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more complexes formed in RTK activation. After binding, molecular tags are released and separated from the assay mixture for analysis.
REFERENCES:
patent: 4772550 (1988-09-01), Greenquist
patent: 4891324 (1990-01-01), Pease et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5108896 (1992-04-01), Philo et al.
patent: 5192660 (1993-03-01), Reed-Gitomer
patent: 5436128 (1995-07-01), Harpold et al.
patent: 5480968 (1996-01-01), Kraus et al.
patent: RE35491 (1997-04-01), Cline et al.
patent: 5769074 (1998-06-01), Barnhill
patent: 5800999 (1998-09-01), Bronstein et al.
patent: 5804396 (1998-09-01), Plowman
patent: 5874542 (1999-02-01), Rockwell et al.
patent: 5886238 (1999-03-01), Schaap et al.
patent: 5968511 (1999-10-01), Akita et al.
patent: 6001573 (1999-12-01), Roelant
patent: 6025128 (2000-02-01), Veltri
patent: 6110109 (2000-08-01), Hu
patent: 6248546 (2001-06-01), Khosravi et al.
patent: 6270963 (2001-08-01), Stevens
patent: 6358682 (2002-03-01), Jaffee
patent: 6370478 (2002-04-01), Stoughton
patent: 6383740 (2002-05-01), Collins
patent: 6388063 (2002-05-01), Plowman et al.
patent: 6417168 (2002-07-01), Greene et al.
patent: 6489116 (2002-12-01), Wagner
patent: 6569093 (2003-05-01), Iliff
patent: 6573043 (2003-06-01), Cohen et al.
patent: 6627196 (2003-09-01), Baughman
patent: 6627400 (2003-09-01), Singh et al.
patent: 6631330 (2003-10-01), Poynard
patent: 6666820 (2003-12-01), Poole
patent: 6727072 (2004-04-01), Spaulding et al.
patent: 6773897 (2004-08-01), Herman
patent: 2002/0172984 (2002-11-01), Holland
patent: 2003/0013126 (2003-01-01), Singh
patent: 2003/0170734 (2003-04-01), Williams
patent: 2003/0190689 (2003-10-01), Crosby
patent: 2003/0207278 (2003-11-01), Khan
patent: 2003/0207403 (2003-11-01), Paszty
patent: 2003/0235816 (2003-12-01), Slawin
patent: 2004/0018528 (2004-01-01), Morimoto
patent: 2004/0018562 (2004-01-01), Rouhani
patent: 2004/0023288 (2004-02-01), Ridder
patent: 2004/0029194 (2004-02-01), Parish
patent: 2004/0033542 (2004-02-01), Frackelton
patent: 2004/0063114 (2004-04-01), Singh
patent: 2004/0103001 (2004-05-01), Mazar
patent: 2004/0106132 (2004-06-01), Huang
patent: 2004/0197815 (2004-10-01), Singh
patent: 2005/0079565 (2005-04-01), Chan-Hui et al.
patent: WO 97/00446 (1997-01-01), None
patent: WO 98/42736 (1998-10-01), None
patent: WO 99/42838 (1999-08-01), None
patent: WO 01/57530 (2001-08-01), None
patent: WO 03/045990 (2003-06-01), None
patent: WO 03/100557 (2003-12-01), None
patent: WO 2004/000102 (2003-12-01), None
patent: WO 2004/008099 (2004-01-01), None
patent: WO 2004/009798 (2004-01-01), None
Ady, et al., “Detection of HER-2
eu-positive circulating epithelial cells in prostate cancer patients”, British Jouranal of Cancer, 2004, 90:443-448.
Agus, et al., “A Potential Role for Activated HER-2 in Prostate Cancer”, Seminars in Oncology, 2000, 27:76-100.
Agus, et al., “Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth”, Cancer Cell, 2002, 2:127-137.
Ahram, et al., “Proteomic Analysis of Human Prostate Cancer”, Molecular Carcinogenesis, 2002, 33:9-15.
Albanell, et al., “Mechanism of Action of Anti-HER2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2C4”, New Trends in Cancer for the 21stCentury, 2003, 253-268.
Alimandi, et al., “Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas”, Oncogene, 1995, 10:1813-1821.
Andersen, “Determination of Estrogen Receptors in Paraffin-Embedded Tissue”, Acta Oncologica, 1992, 31:611-627.
Angers, et al., “Dimerization: An Emerging Concept for G Protein-Coupled Receptor Ontogeny and Function”, Annu. Rev. Pharmacol. Toxicol., 2002, 42:409-435.
Antonsson, et al., “An in Vitro 96-Well Plate Assay of the Mitogen-Activated Protein Kinase Cascade”, Analytical Biochemistry, 1999, 267:294-299.
Arteaga, “Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?”, The Oncologist, 2002, 7:31-39.
Auerbach, et al., “Proteomic approaches for generating comprehensive protein interaction maps”, Targets, 2003, 2:85-92.
Baselga, “Anti-EGFR therapy: A new targeted approach to cancer treatment”,Oncology Biotherapeutics, 2002, 2:2-36.
Baselga, “A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization”, Cancer Cell, 2002, 2:93-95.
Baselga, et al., “Mechanism of action of anti-HER2 monoclonal antibodies”, Annals of Oncology, 2001, 12:S35-S41.
Bast, et al., “Coexpression of the HER-2 Gene Product, p185HER-2, and Epidermal Growth Factor Receptor, p170EGF-R, on Epithelial Ovarian and Normal Tissues”, Hybridoma, 1998, 17:313-321.
Beaudet, et al., “Homogenous Assays for Single-Nucleotide Polymorphism Typing Using AlphaScreen”, Genome Research, 2001, 11:600-608.
Becker, “Signal transduction inhibitors-a work in progress”, Nature Biotechnology, 2004, 22:15-18.
Bei, et al., “Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma”, Journal of Pathology, 2001, 195:343-348.
Bichsel, et al., “Cancer Proteomics: From Biomarker Discovery to Signal Pathway Profiling”, The Cancer Journal, 2001, 7:69-78.
Blagoev, et al., “A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling”, Nature Biotechnology, 2003, 21:315-318.
Blakely, et al., “Epidermal growth factor receptor dimerization monitored in live cells”, Nature Biotechnology, 2000, 18:218-222.
Blume-Jensen, et al., “Oncogenic kinase signalling”, Nature, 2001, 411: 355-365.
Brockhoff, et al., “Epidermal Growth Factor Receptor, c-erbB2 and c-erbB3 Receptor Interaction and Related Cell Cycle Kinetics of SK-BR-3 and BT474 Breast Carcinoma Cells”, Cytometry, 2001, 44:338-348.
Bohula, et al., “Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment”, Anti-Cancer Drugs,2003, 14:669-682.
Brandt, et al., “c-erB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells”, The FASEB Journal, 1999, 13:1939-1949.
Brockhoff, et al., “Epidermal Growth Factor Receptor, c-erbB2 and c-erbB3 Receptor Interaction and Related Cell Cycle Kinetics of SK-BR-3 and BT474 Breast Carcinoma Cells”, Cytometry, 2001, 44:338-348.
Chow, et al., “Epression profiles of ErbB Family Receptors and Prognosis in Primary Transitional Cell Carcinoma of the Urninary Bladder”, Clinical Cancer Research, 2001, 7:1957-1962.
Dean, et al., “Cell Surface Density of p185c-erbB-2Determines Susceptibility to Anti-P185c-erbB-2Ricin A Chain (RTA) Immunotoxin Therapy Alone and in Combination with Anti-P170EGFRRTA in Ovarian Cancer Cells”, Clinical Cancer Research, 1998, 4:2545-2550.
DePrimo, et al., “Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification”, BMC Cancer, 2003, 3:1-12.
Dikic, “CIN85/CMS family of adaptor mole
Chan-Hui Po-Ying
Mukherjeei Ali
Pannu Harprit S.
Singh Sharat
Tang Mengxiang
Gamett Daniel C
Monogram BioSciences, Inc.
Rao Manjunath
LandOfFree
Receptor tyrosine kinase signaling pathway analysis for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Receptor tyrosine kinase signaling pathway analysis for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Receptor tyrosine kinase signaling pathway analysis for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3930561